• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » David Ho

Articles by David Ho

Samsung Biologics plant

Samsung Biologics buys Biogen's stake in Samsung Bioepis for $2.3B

Feb. 1, 2022
By Gina Lee and David Ho
Samsung Biologics Co. Ltd. has agreed to buy out Biogen Inc.’s stake in the joint venture Samsung Bioepis Co. Ltd. for $2.3 billion. Biogen will receive $1 billion in cash at closing and $1.25 billion in deferred payments of $812.5 million due at the first anniversary and $437.5 million due at the second anniversary of the closing of the transaction. Biogen is also expected to receive up to $50 million upon achievement of certain commercial milestones.
Read More
Screenshot of surgical video demonstrating Rsip Vision's virtual measurement technology

Rsip Vision presents intra-op virtual measurements for laparoscopic and robot-assisted surgeries

Jan. 31, 2022
By David Ho
Israel and U.S.-based Rsip Vision Ltd. has released a new supporting technology for intraoperative video analysis. The company says its offering provides real-time and accurate anatomical measurements in surgical videos. This supports a variety of clinical use cases, such as bariatric surgery and small bowel resection.
Read More
Samsung Biologics plant

Samsung Biologics buys Biogen's stake in Samsung Bioepis for $2.3B

Jan. 28, 2022
By Gina Lee and David Ho
Samsung Biologics Co. Ltd. has agreed to buy out Biogen Inc.’s stake in the joint venture Samsung Bioepis Co. Ltd. for $2.3 billion. Biogen will receive $1 billion in cash at closing and $1.25 billion in deferred payments of $812.5 million due at the first anniversary and $437.5 million due at the second anniversary of the closing of the transaction. Biogen is also expected to receive up to $50 million upon achievement of certain commercial milestones.
Read More
Pills spilling out of prescription bottle

Everest acquires rights to 3CL protease inhibitors to develop antivirals for COVID-19

Jan. 18, 2022
By David Ho
Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.
Read More

SCG acquires induced pluripotent stem cell tech from Singapore’s A*STAR

Jan. 18, 2022
By David Ho
SCG Cell Therapy Pte. Ltd. has acquired rights to human induced pluripotent stem cell technology from Singapore’s Agency for Science, Technology and Research (A*STAR)’s Accelerate Technologies Pte. Ltd. to support the development of natural killer (NK) cell therapies for leukemia, liver cancer, gastric cancer and other solid tumors.
Read More
Pills spilling out of prescription bottle

Everest acquires rights to 3CL protease inhibitors to develop antivirals for COVID-19

Jan. 14, 2022
By David Ho
Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.
Read More

SCG acquires induced pluripotent stem cell tech from Singapore’s A*STAR

Jan. 14, 2022
By David Ho
SCG Cell Therapy Pte. Ltd. has acquired rights to human induced pluripotent stem cell technology from Singapore’s Agency for Science, Technology and Research (A*STAR)’s Accelerate Technologies Pte. Ltd. to support the development of natural killer (NK) cell therapies for leukemia, liver cancer, gastric cancer and other solid tumors.
Read More
Hands holding gears

Junshi Biosciences starts 2022 with two licensing deals

Jan. 11, 2022
By David Ho
Barely two weeks into the year, Shanghai Junshi Biosciences Co. Ltd. has already locked down an out-licensing deal and an in-licensing agreement. In a follow-up to their $1.1 billion deal a year ago, Coherus Biosciences Inc. has moved ahead with the right to exercise its option to license Junshi’s JS-006, a recombinant humanized IgG4k monoclonal antibody targeting T cell immunoglobulin and ITIM domain protein (TIGIT). Separately, Junshi has in-licensed antibody “modules,” or Dotbodies, from Dotbio Pte. Ltd. for use in oncology and the development of several multispecific antibodies.
Read More
Flag of India

India seeking to improve domestic pharma and med-tech ecosystems with new guidelines

Jan. 4, 2022
By David Ho
India’s Department of Pharmaceuticals (DOD) released draft guidelines to boost research and development in its pharmaceutical and medical device industries. The document touched on the reasons for a dedicated R&D and innovation policy, which involved reducing import dependence, increasing the speed of biologic and biosimilar development cycles, and tackling infrastructural challenges.
Read More
Flag of India

India seeking to improve domestic pharma and med-tech ecosystems with new guidelines

Dec. 28, 2021
By David Ho
India’s Department of Pharmaceuticals (DOD) released draft guidelines to boost research and development in its pharmaceutical and medical device industries. The document touched on the reasons for a dedicated R&D and innovation policy, which involved reducing import dependence, increasing the speed of biologic and biosimilar development cycles, and tackling infrastructural challenges.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 71 72 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe